"We see significant potential in increasing survival of these patients — over 20% had complete or near-complete tumor shrinkage.” - CEO Frank Bedu-Addo discusses positive results from our VERSATILE-002 trial for 1L R/M HNSCC on @ProgressPotent1 Podcast:

Frank Bedu-Addo, PhD, President and CEO of PDS Biotech comments on the completion of patient recruitment of the metastatic colorectal cancer cohort in @theNCI-led Stage 1 clinical trial, and the progression of enrollment into Stage 2: $PDSB

The metastatic colorectal cancer cohort in @theNCI-led multi-cohort study of PDS01ADC in combination with floxuridine (FUDR) demonstrated promising response rate, triggering enrollment expansion under a Simon two-stage trial design. Learn more:

The study met the pre-set criteria for expansion into Stage 2 of the study of a confirmed objective response by RECIST v1.1 criteria in at least 6/9 patients. For details:

Patient recruitment has been completed in Stage 1 of a clinical trial of PDS01ADC administered systemically in combination with floxuridine (FUDR) administered by HAIP for patients with metastatic colorectal cancer.

Frank Bedu-Addo, Ph.D., CEO of PDS Biotech sat down with @irat1onal on the Progress, Potential, and Possibilities Podcast, to discuss drug development, the future of oncology, and the exciting potential of the Versamune® T-cell platform. Watch here: $PDSB.

Katharine A. Price, MD discussed some of the issues with current treatments for recurrent/metastatic HPV-positive cancers and the need for new treatment options during our recent KOL event. Listen to the full event here: $PDSB

PDS Biotechnology is developing Versamune® HPV as a combination treatment with pembrolizumab to better address HPV16-positive HNSCC, a disease type with significant unmet need. Learn more about the potential of Versamune® HPV from our KOL event here: $PDSB

There is a need for novel treatments that can help address HPV16-positive HNSCC, a disease type with rising incidence and poor prognosis. Learn more about HPV16-positive #HNSCC from @ICR_London's Kevin Harrington, MBBS, PhD during our KOL event: $PDSB

Versamune® HPV has the potential to stimulate a potent targeted T cell attack against HPV16+ cancers, which are expected to make up ~60% of R/M HNSCC cases in the U.S. and Europe by 2030. Learn more about Versamune® HPV from our recent KOL event: $PDSB

Katharine Price, MD (Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center) shares Versamune® HPV's potential as a combination therapy with pembrolizumab to enhance immune response and deliver meaningful clinical benefits for R/M HPV16+ HNSCC:

Versamune® HPV is being evaluated in a Ph.3 clinical trial in combination with pembrolizumab as a first-line treatment for HPV16+ HNSCC, a disease with rapidly increasing incidences in the U.S. and Europe. Listen to our recent KOL event to learn more:

Kevin Harrington, MBBS, PhD (The Institute of Cancer Research, United Kingdom) shared insights on the prevalence of HPV16-related diseases, and the rise of HPV-positive head and neck cancer during our recent KOL event. Watch the full webcast replay: $PDSB

Going on now: Our KOL event is discussing the rapidly increasing incidence of HPV16-positive HNSCC. Tune in to learn more about the unmet need and current treatment landscape for recurrent/metastatic HPV16-positive HNSCC here: $PDSB

Today at 12:00PM ET, PDS Biotech will host a KOL event to discuss Versamune® HPV, the changing landscape of HNSCC in context with the Merck KN-689 study, and the rapidly increasing incidence of HPV16+ HNSCC in the U.S. and Europe. Register here: $PDSB

Tomorrow from 12:00 PM-1:30 PM ET, PDS Biotech will be joined by Key Opinion Leaders to discuss Versamune® HPV for the treatment of HPV16+ HNSCC. A live Q&A will follow the discussion. Register here: $PDSB

PDS Biotech's KOL event on Tuesday, June 17th at 12:00 PM ET will discuss the changing landscape of HNSCC in context with the Merck KN-689 study and the rapidly increasing incidence of HPV16+ HNSCC in the U.S. and Europe. To register: $PDSB

During the KOL event, a panel will discuss the 1L R/M HNSCC treatment landscape & the view of HPV-positive & HPV-negative HNSCC as distinct diseases with different underlying causes and pathology, as well as identification & treatment of HPV16+ HNSCC.

PDS Biotech will host a virtual KOL event on Tuesday, June 17th at 12:00 PM ET featuring Kevin Harrington, MBBS, PhD and Katharine A. Price, MD, to discuss the unmet need and current treatment landscape for r/m HPV16+ HNSCC. For details: $PDSB

PDS Biotech Chief Medical Officer Dr. Kirk Shepard, M.D., comments on the updated positive data from VERSATILE-002 trial presented at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. More info: #ASCO25